

1 **Research Article**

2

3 Title:

4 **Evaluation of the Practicability of a Finger-Stick Whole-Blood SARS-Cov-2 Self-Test**
5 **Adapted for the General Population.**

6

7

8 **Authors**

9 Thierry Prazuck ¹, Jean Phan Van ², Florence Sinturel ³, Fredrique Levray ³, Allan Elie ³,
10 Denise Camera ², Gilles Pialoux ⁴

11 **1** Department of infectious and tropical diseases, CHR Orléans, 14 Avenue de l'Hôpital, 45
12 067, Orléans, France

13 **2** EDF Nuclear Plant, Saint-Laurent-des-Eaux, France

14 **3** EDF Nuclear Plant, Dampierre-en-Burly, France

15 **4** Department of infectious diseases, Hôpital Tenon, Assistance Publique des Hôpitaux de
16 Paris, Sorbonne Université, Paris, France

17

18 **Corresponding Author**

19 Thierry Prazuck
20 Service des maladies infectieuses
21 CHR Orléans, 14 avenue de l'hôpital, 45 067 Orléans, France
22 thierry.prazuck@chr-orleans.fr

23

24

25 **Abstract**

26 Background

27 COVID-19 (COroNaVIrus Disease 2019) is an infectious respiratory disease caused by the
28 novel SARS-CoV-2 virus. Rapid Diagnostic Tests (RDTs) have been developed to detect
29 specific antibodies, IgG and IgM, to SARS-CoV-2 virus in human whole blood and easily
30 usable by the general population are needed in order to alleviate the lockdown that many
31 countries have initiated in response to the growing COVID-19 pandemic. A real-life study has
32 been conducted in order to evaluate the performance of the COVID-PRESTO[®] RDT and the
33 results have been submitted for publication and are currently under review. Even if this test
34 showed very high sensitivity and specificity in a laboratory setting when used by trained
35 professionals, it needs to be further evaluated for practicability when used by common folk in
36 order to be approved by health authorities for in-home use

37

38 Methods

39 142 participants were recruited between March 2020 and April 2020 among non-medical
40 populations in central France (nuclear plants workers, individuals attending the Orleans
41 University Hospital vaccination clinic and Orleans University Hospital non-medical staff).
42 Instructions for use with or without a tutorial video was made available to the volunteers. Two
43 separate objectives were pursued: evaluation of the capability of participants to obtain an
44 interpretable result, and evaluation of the users' ability to read the results.

45

46 Results

47 88.4 % of the test users judged the instruction for use leaflet to be clear and understandable.
48 99.3 % of the users obtained a valid results and according to the supervisors 92.7% of the
49 tests were properly performed by the user. Overall, 95% of the users gave positive feedback
50 toward the COVID PRESTO[®] as a potential self-test. No influence of age and education was
51 observed.

52

53 Conclusion

54 COVID-PRESTO[®] was successfully used by an overwhelming majority of participants and its
55 utilization was judged very satisfactory, therefore showing a promising potential as a self-test
56 to be used by the general population. This RDT can become an easy-to-use tool to help
57 know whether individuals are protected or not, particularly in the perspective of a second
58 wave or a mass vaccination program.

59

60 Keywords: SARS-CoV-2; COVID-19; Rapid Diagnostic Test; Self-test

61 Introduction

62 In Wuhan, China the end of the year 2019 marked the emergence of a new type of
63 pneumonia caused by a then-unknown agent. Shortly after the first reports of the disease,
64 the Chinese health authorities and the World Health Organization announced that a newly-
65 discovered type of coronavirus was responsible for the disease. This new virus was named
66 SARS-CoV-2 (Sever Acute Respiratory Syndrome-CoronaVirus-2). This virus is a new
67 member of the coronavirus family that already includes SARS-CoV and MERS-Cov
68 responsible for the SARS outbreak in 2003, and an ongoing outbreak that started in 2012 in
69 the Middle East, respectively.

70 The disease caused by the SARS-CoV-2 virus is called COVID-19 (COronaVirus Disease-
71 2019). The site of infection is located on the upper/lower respiratory tract [1]. The mean
72 incubation period is approximatively 5.2 days and the most common symptoms are dry
73 cough, fever and fatigue. Other symptoms include anosmia (loss of smell), ageusia (loss of
74 taste), headache, sore throat and in the most severe cases acute respiratory distress
75 syndrome.

76 Within the last 6 months, according to the Johns Hopkins University Coronavirus resource
77 center the COVID-19 pandemic has spread over 188 countries; leaving very few regions of
78 the world untouched. At the end of January 2020, the WHO has declared this outbreak a
79 global health emergency and the mark of 100 000 deaths was reached on April 12th leading
80 to a little less than 350 000 deaths on May 26th for a total of 5 519 878 confirmed cases.
81 Governments have taken extreme measures to try slow the spreading of the virus by
82 imposing strict social distancing rules and it is estimated that 1.7 billion people have been
83 confined home worldwide.

84 In most countries, these measures have been effective in slowing down the transmission of
85 the virus. In May 2020, several governments started easing the confinement rules but
86 questions remain in regards to how to test, control and track every case in a large population
87 at least until an effective treatment or vaccine can be found. To this end, the development of
88 new testing tools that could be distributed at a large scale in the population is crucial.
89 Serological tests able to detect the specific antibodies against the SARS-CoV-2 in people
90 seem to be particularly good candidates because there are fairly easy to use and execute
91 without an extensive training.

92 The AAZ COVID-PRESTO[®] is a Rapid Diagnostic Tests (RDTs), easy-to-use device based
93 on lateral flow chromatographic immunoassay from a single drop of blood (Figure 1). It has
94 been evaluated in terms of sensitivity and specificity and showed good results that have
95 been submitted for publication and currently under review [2]. Those results were obtained in
96 a controlled setting where the test was performed by trained professionals. In order to be
97 suitable as a self-test for the general population, COVID-PRESTO[®] has to be evaluated for
98 practicability, i.e. its capacity of being able to be performed by untrained individuals. The aim
99 of this study was to evaluate the COVID-PRESTO[®] test in terms of participants' capability to
100 obtain an interpretable result, and the users' ability to interpret the results.

101

102

103 **Methods and Materials**

104 **Ethics Approval**

105 The study was approved by the Regional Orléans Research and ethics Committee on March
106 17th 2020, and informed consent was obtained from each participant.

107 **Study population**

108 The study volunteers were selected from four different locations in Central France from
109 March 20th 2020 to May 5th, 2020: two nuclear plants, individuals visiting the vaccination
110 clinic of Orleans Regional Hospital and non-medical staff from Orleans Regional Hospital.
111 The decision of recruiting non-medical staff exclusively was made in order to avoid bias due
112 to previous or current experience in blood drawing. A total of 142 volunteers participated to
113 the study. Two were excluded from the analysis because they did not fill in the questionnaire.

114 A 2 steps design similar to the design used to validate an HIV self-test was used for this
115 study [3].

116 **Substudy 1: Usage of the self-test**

117 Each volunteer was invited to read the test's information for use replaced and/or associated
118 to an instructional video in order to give clearer instructions.

119 The instructions were the following:

Table 1: Instruction for use.

autotest COVID® is a screening test for IgG and IgM antibodies against SARS-CoV-2 based on a blood sample taken from the tip of the finger.
autotest COVID® allows the determination of an immunization against SARS-CoV-2 which makes it possible to affirm, even in the absence of symptoms, the contact with the virus and a supposed acquired protective immunity.

autotest COVID® is a one-time use in-vitro diagnostic test.
autotest COVID® is intended for use by a layperson in a private setting.
The test takes about 5 minutes to perform and the wait time before reading the result is 10 minutes.
You will need a watch, clock, or other timing device. Please carefully read all of the following instructions prior to using the test.

Content of the kit

- Foil pouch containing the test device and a desiccant packet.
- One disinfectant wipe
- 1 vial of buffer
- 1 safety lancet
- 1 capillary blood pipet (10µl)

Test procedure:

- Step 1 : Clean the fingertip with the disinfectant wipe and let it dry
- Step 2 : Prick the fingertip using the safety lancet
- Step 3 : Press the fingertip to form a drop of blood
- Step 4 : Collect the blood sample using the capillary pipet
- Step 5 : Discharge the pipet into the Sample well "S"
- Step 6 : Put 2 drop of buffer into Buffer well "B"
- Step 7 : Read the result of the test after 10 minutes

120 Every volunteer had to use the lancet needle to prick the side of the fingertip to let a large
121 drop of suspended blood form, collect the drop with a 10 µl capillary micropipette that filled
122 automatically, transfer the blood into the sample well and finally, add two drops of buffer in
123 the buffer well.

124 Each participant was asked to fill in a satisfaction questionnaire on the test as a future self-
125 test intended for the general population (Table 2).

126 The test user was monitored by an observer (Occupational health physician in the nuclear
127 plants, trained nurse or physician in the Orleans Regional hospital) who could assist the
128 user, if asked to, and give his/her feedback on the execution of the different tasks. This
129 feedback could be different from the user's personal opinion (Table 3).

130 **Substudy 2: Reading and interpretation of the results:**

131 Each participant was shown a basket containing 6 standardized test results (2 positives, 2
132 negatives and 2 invalids). The participant had to randomly choose three out of the six
133 standardized tests and write down the results for each test. A supervisor was in charge to
134 collect the responses and assess their correctness.

135

136 **Table 2. Satisfaction questionnaire**

Satisfaction Questionnaire	
1.	Did you find the test's instructions for use that was provided to you, clear and comprehensible?
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
2.	Did you find the instructional video, clear and comprehensible?
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
3.	Did you manage to collect a sufficient drop(s) of blood?
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
4.	Did you manage to fill the pipette?
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
5.	Did you manage to deposit the blood and buffer in the wells without mistake?
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
6.	Did you obtain a result (at least one band)?
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
7.	What is your opinion regarding the utilization of this test as a self-test?
<input type="checkbox"/>	Bad
<input type="checkbox"/>	Mediocre
<input type="checkbox"/>	Good
<input type="checkbox"/>	Very good
<input type="checkbox"/>	Excellent
8.	What is your opinion regarding the readability and the interpretation of this test?
<input type="checkbox"/>	Bad
<input type="checkbox"/>	Mediocre
<input type="checkbox"/>	Good
<input type="checkbox"/>	Very good
<input type="checkbox"/>	Excellent

137

138 **Table 3. Supervisor's Opinion**

Supervisor's Opinion	
1.	Was the supervisor's assistance requested by the participant?
<input type="checkbox"/>	Yes
<input type="checkbox"/>	No
2.	What is your opinion regarding the execution of this test by the participant?
<input type="checkbox"/>	Bad
<input type="checkbox"/>	Mediocre
<input type="checkbox"/>	Good
<input type="checkbox"/>	Very good
<input type="checkbox"/>	Excellent

139

140

141 **Data Analysis**

142 Population were described in terms of %, and mean values standard deviation, range and
 143 median values. Demographics characteristics such as age and education level, associated
 144 with the responses to the questionnaire were evaluated using univariate and stratified
 145 analyses and the Cochran-Mantel-Haenszel test. In case of overall differences between
 146 groups, *post hoc* Fisher or χ^2 tests with Bonferroni correction were applied for two-group
 147 comparisons.

148

149 **RESULTS**

150 Overall, 142 volunteers were selected to participate to the study, among those 2 did not fill in
 151 the Satisfaction questionnaire and 96 participated to Substudy 2. The distribution of gender
 152 was in favor of men, twice as much represented than women. Four different age classes
 153 were defined 20-29, 30-39, 40-49 and ≥ 50 . Three education level classes were defined
 154 according the toe International Classification of Education (2011 version): Level 3 or below,
 155 Level 4 or 5, and Level or above.

156 The demographics characteristics are provided in Table 4:

157 **Table 4. Demographics characteristics of the study population**

Characteristics	Substudy 1		Substudy 2	
	N=142		N=96	
	N (%)	%	N (%)	%
Study Site:				
Dampierre Nuclear Plant	45	32.1	23	24.0
St Laurent Nuclear Plant	37	26.4	15	15.6
Orleans Regional Hospital	58	41.4	58	60.4
Age				
20-29	32	22.5	25	26.0
30-39	45	31.7	30	31.3
40-49	46	32.4	29	30.2
≥ 50	19	13.4	12	12.5
Gender				
Male	95	67.8	56	58.3
Female	45	32.2	40	41.7
Education Level*				
Level 3 or below	23	16.4	18	18.8
Level 4 or 5	75	53.6	48	50.0
Level 6 or above	42	30.0	30	31.3

158 *According to the International Standard Classification of Education 2011

159 **Substudy 1:** A total of 103 participants read the instructions for use provided with the test.
 160 Among those 67 volunteers read the instructions and watched the video. 91 participants
 161 (88.4%) found the written instructions to be clear and comprehensible. 106 participants
 162 watched the video making it 39 volunteers that watched the video as the only instruction
 163 medium. Among these 106 volunteers, 96 (90.6%) found the video to be clear and
 164 comprehensible. A subgroup analysis showed that there was no difference on the

165 comprehension of the instructions notice when age or education level was considered.
166 However, there was a statistical difference in the comprehension of the instructional video
167 among the groups. Indeed, the video was judged comprehensible by only 77.8% of the
168 participants aged 29 or less compared to 91.7% (30-39), 96.7% (40-49) and 100.0% (≥ 50) by
169 the other groups (Cochran-Mantel-Haenszel test's overall $p= 0.0465$). However, *post hoc*
170 Fisher's tests with Bonferroni correction revealed that the proportion of users that found the
171 video comprehensible in the 20-29 range was not significantly lower when groups were
172 compared by pairs, meaning that age has little influence on the comprehension of the
173 instructional video. There was also an overall statistical difference in the comprehension of
174 the video when education level was considered as an influencing factor (Cochran-Mantel-
175 Haenszel test's overall $p= 0.0235$). Nevertheless, when two-group comparisons were
176 performed using a Fisher's t test or a χ^2 with a Bonferroni correction, no difference was
177 observed. These results show that education level did not have an effect on the
178 understanding of the instructional video. Taken together these results show that the
179 instructions were well received and understood by all participants with little to no impact of
180 age or education level on their comprehension.

181 The COVID-PRESTO[®] technical practicability was assessed by analyzing the participants'
182 responses to the satisfaction questionnaire. 130 out of the 140 participants (92.8%) who filled
183 in the questionnaire, were able to draw enough blood using the lancet needle on their
184 fingertips. However, the ten participants that could not collect the recommended quantity of
185 blood were able to proceed with the subsequent steps. 128 participants (91.4%) succeeded
186 in filling up the pipette with blood on the first try and without assistance. 135 testers (96.4%)
187 were able to correctly deposit both the blood and the buffer in their respective wells. Among
188 those, 7 participants needed assistance to fill the pipette. At the end of the procedure, nearly
189 all participants (139/140, 99.3%) declared to have been able to get a valid result (defined by
190 a pink band in the control lane).

191 In terms of overall satisfaction, 133/140 participants (95%) rated positively the COVID-
192 PRESTO[®] (defined as "Good", "Very Good" or "Excellent"), based on the ease of execution
193 of the test's procedures. 45% of the participants rated the test as good and 50% as "Very
194 Good" or "Excellent". A subgroup analysis revealed that age and education had no impact
195 whatsoever on the overall satisfaction towards the COVID-PRESTO[®] test.

196 Supervisors were also asked to answer a survey after each participant was done with the
197 test's procedures. It is however, important to point out that only 122 answers to the
198 supervision survey were collected. During these supervised sessions, 92/122 (76.4%)
199 participants did not ask for assistance to the supervisor. Only 30 participants requested an
200 assistance mainly for tips on how to take off the cap of the needle as well as on how to use
201 the pipette. The subgroup analysis showed that almost half of the participants (43.8%) with
202 an education level of 4 or 5 requested assistance and this proportion was statistically higher
203 when compared to the proportion of participants having requested assistance in the other
204 groups (Overall Cochran-Mantel-Haenszel test's $p= 0.0004$; χ^2 p value of 0.009 and 0.006
205 vs. level ≤ 3 and ≥ 6 respectively). The supervisors' opinion on the execution of the
206 procedures by the participants was collected and the execution was rated as good or better
207 for 113/122 (92.7%) volunteers. 45.9% of the volunteers were rated as "Good", 36.1% as
208 "Very Good" and 10.7% as "Excellent". When age and education parameters were
209 considered during a subgroup analysis, no difference were observed between the categories
210 in terms execution ratings.

211 **Substudy 2:** 96 volunteers took part of this second phase down from the 140 participants in
212 the first phase. The volunteers had to randomly choose 3 tests out of 6 and assess their
213 readability. Among these 96 participants 94 (97.9%) judged the readability of the sorted test

214 to be good or better (“very good” or “excellent”). 41.2% of the volunteers rated the test
215 legibility as “Good”, 41.7% as “Very Good” and 14.5% as “Excellent”. Only two individuals
216 incorrectly interpreted the test by judging an invalid test as valid. The confusion originated
217 from the fact that they had not understood that the control lane had to be pink instead of
218 blue. Overall, 288 tests were read and only 2 were not interpreted correctly resulting in a
219 99.3% success rate. These two participants were 26 and 42 years old and with an
220 educational level of 3 and 4 respectively. A subgroup analysis considering the age and
221 education level classes showed that these two parameters don’t have any influence of the
222 ability of the participant to correctly interpret the test results.

223 DISCUSSION

224 This study had the objective to test the adequacy of one Rapid Diagnosis Test for Covid-19
225 in regards to a potential release for the general population. This test was developed to detect
226 the presence of antibodies targeted against the SARS-CoV-2 as an indirect marker of prior
227 infection.

228 The use of such tests with the help of appropriate instructions and interpretation guidelines
229 could prove to be essential in supporting the current public health effort. Indeed, these tests
230 would provide intelligence data on the dissemination of virus across the population and
231 therefore would a valuable tool to help comprehend the epidemics. The use of such tests will
232 be also essential to know immune status of patients in view of a second wave or a possible
233 mass vaccination program [4].

234 An extensive list of the test available worldwide can be found in the FIND foundation website
235 (https://www.finddx.org/covid-19/pipeline/?section=immunoassays#diag_tab). Around a
236 hundred of COVID-19 serological tests are currently commercially available in the US
237 through the Emergency Use Authorization (EUA) granted to the US Centers for Disease
238 Control and Prevention by the Food and Drug Administration (FDA) [5]. The FDA has
239 provided guidance for manufacturers of serological test in order to promote and facilitate
240 rapid market access on the basis that such tests could help provide crucial information about
241 the prevalence of COVID-19 infections in different communities [6]. However, an NIH
242 independent evaluation has shown that a concerning number of commercial serological test
243 are not being appropriately promoted or show poor performance [6]. In Europe, according to
244 regulations, manufacturers should submit data regarding "handling suitability of the device in
245 view of its intended purpose for self-testing" for assessment by notified bodies before making
246 it available to the public [7]. The European Centre for Disease Prevention and Control reports
247 that several COVID-19 RDT are being marketed with incomplete and even sometimes
248 fraudulent documentation and unsubstantiated claims, some of these test being sold as self-
249 tests and thus, several European countries has banned the marketing of such tests until
250 further notice [8] Therefore, there is a crucial need of more documented studies regarding
251 those tests [9,10].

252 From a regulatory standpoint, "self-testing" is a more stringent regulated category of *in vitro*
253 diagnosis tests compared to the regular kind, intended for professional use only, and the
254 French health authority (Haute Autorité de Santé, HAS) estimates that in absence of reliable
255 data regarding the available self-tests it is premature to promote their use [11]. COVID-
256 PRESTO[®] aims to be one of the first SARS-CoV-2 serological test to be officially approved
257 as a reliable and accurate self-test in order to offer a viable option for large scale testing. It is
258 important to keep in mind that these tests are not designed to detect an ongoing infection but
259 rather a prior infection which would give intelligence about the true prevalence of the virus.
260 However, a positive test will not mean that the tested individual is no longer infectious but will
261 give the information that at some point in the past. As of today, there is no solid evidence that
262 a prior infection will offer a strong immunity towards a second exposure and if so for how
263 long [12], nevertheless, a pre-published study demonstrated that most of the patients having
264 presented a mild form of the COVID-19, developed neutralizing antibodies [4].

265 COVID-PRESTO[®] has recently been evaluated for performance and showed a sensitivity
266 ranging from 69% for patients with symptoms that occurred from 11 to 15 days before the
267 date of test and 100% in patients who experienced first symptoms more than 15 days before
268 the test. These results are currently being reviewed for publication [2]. However, for it to be
269 approved as a self-test, a practicability study was needed in order to assess the feasibility of
270 the test by untrained individuals with different education levels. First of all this study showed
271 that the instruction materials provided with the test are clear and comprehensible regardless
272 of the user's age or education level. However, our results showed that age or education level
273 may slightly influence the comprehension of non-written instructions, i.e. instructional video.
274 This finding indicates that it may be necessary to include a variety of instruction media along
275 with the test to ensure its comprehension by a broader audience. These media may include
276 written instructions, cartoons or videos.

277 We observed that the education level influenced the fact that whether or not the participant
278 asked for assistance. Nevertheless, no influence of the age nor the education level on either
279 the ability to correctly read the test or to execute the procedures according to the
280 supervisors, was observed in our study. This strongly suggest that the execution of the test is
281 accessible to a wide range of persons. Finally, this study revealed that the COVID-PRESTO[®]
282 is judged practical with a global satisfaction rate of 95% by the users and is favorably seen
283 as a potential self-test.

284 Data are scarce regarding the performance of the existing serological COVID-19 test and to
285 our knowledge this is the first practicability study regarding a COVID-19 RDT making it
286 difficult to compare our results to other devices. However, that this kind of study is necessary
287 before making a self-test available to general public in order to, in one hand, avoid confusion
288 about false positive results thus leading to unnecessary demands of health services and, in
289 the other hand, avoid false negative results potentially leading to underestimation of the virus
290 presence across population.

291 The ease of understanding the instructions is always a challenge when designing a self-test
292 but our study shows that the COVID-PRESTO[®] test procedures fare well in that regard.
293 However, feedback from users showed that there is still room for improvement regarding the
294 instructions and video. Indeed, some of the volunteers had legitimate questions on technical
295 procedures such as the handling of the lancet needle, and the use of the pipette. It is
296 important to point out that in our study, socio-demographic parameters such as age and
297 education, did not influence any of the tested parameters suggesting that the instructions as
298 well as the procedures are sufficiently clear and simple to be executed by the general public.
299 The next step for a person that has been tested positive for the Covid-19 is knowing if he/she
300 is still contagious and whether he/she has to isolate from his/herself from others. Given the
301 data currently available regarding the SARS-CoV-2, although it has been recently
302 demonstrated that individuals who have recovered form a mild form of the COVID-19
303 possess neutralizing antibodies [4], we can only assume without certainty that infection with
304 the virus generates protective immunity [12],. It is therefore important that the test
305 instructions includes clear and understandable guidance regarding the actions that need to
306 be taken in case of a positive or negative results, in order to avoid relaxation of the safety
307 measures. To this aim, in case of a positive IgM test, the instructions for use of the COVID-
308 PRESTO[®] test will recommend to seek care from a Primary Care provider and undergo

309 further testing (PCR) to confirm/invalidate the presence of an active infection. In case of a
310 confirmed active infection, the instructions will enjoin the patient to observe a strict 14 days
311 quarantine.

312 **Conclusion**

313 These 2 substudies indicate that the finger-stick COVID PRESTO[®] self-test is practical and
314 that test users correctly read the results. The COVID-PRESTO[®] should be considered as a
315 suitable candidate for a public release in order to provide an additional tool to gather
316 information about the dissemination of the virus across the population.

317 **Contributions**

318 Conceived and designed the experiments: TP and GP. Recruited the participants and
319 conducted the study: JPV, FS, FL, AE and DC. Analyzed the data: TP and GP. Wrote the
320 manuscript: TP and GP.

321

322 **Acknowledgments**

323 The authors would like to thank the technical staff of the Department of Infectious diseases
324 for excellent assistance. Furthermore, the authors thank Thibaut de Sablet of Clinact, France
325 for providing medical writing support/editorial support in accordance with Good Publication
326 Practice (GPP3) guidelines.

327

328 **Declaration of interest**

329 The authors report no conflicts of interest. The authors alone are responsible for the content
330 and the writing of the paper.

331

332 **Funding**

333 COVID-PRESTO[®] tests were provided free of charge by AAZ-LMB.

334 **REFERENCES**

- 335 1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease
336 (COVID-19) outbreak. *Journal of Autoimmunity*. 2020;109: 102433.
337 doi:10.1016/j.jaut.2020.102433
- 338 2. Prazuck T, Colin M, Giachè S, Gubavu C, Seve A, Rzepecki V, et al. Evaluation of
339 performance of two SARS-CoV-2 Rapid whole-blood finger-stick IgM-IgG Combined
340 Antibody Tests. *PLoS ONE*. 2020.
- 341 3. Prazuck T, Karon S, Gubavu C, Andre J, Legall JM, Bouvet E, et al. A Finger-Stick
342 Whole-Blood HIV Self-Test as an HIV Screening Tool Adapted to the General Public.
343 Paraskevis D, editor. *PLOS ONE*. 2016;11: e0146755.
344 doi:10.1371/journal.pone.0146755
- 345 4. Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, et al. Serologic
346 responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern
347 France. *medRxiv*. 2020; 2020.05.19.20101832. doi:10.1101/2020.05.19.20101832
- 348 5. 360DX. Coronavirus Test Tracker: Commercially Available COVID-19 Diagnostic Tests.
349 Available: <https://www.360dx.com/coronavirus-test-tracker-launched-covid-19-tests>
- 350 6. Food and Drug Administration. Policy for Coronavirus Disease-2019 Tests During the
351 Public Health Emergency (Revised). Available:
352 <https://www.fda.gov/media/135659/download>
- 353 7. European Commission. Directive 98/79/EC of the European Parliament and of the
354 Council of 27 October 1998 on in vitro diagnostic medical devices.
- 355 8. European Commission. Guidelines on COVID-19 in vitro diagnostic tests and their
356 performance. 2020. Available:
357 https://ec.europa.eu/info/sites/info/files/testing_kits_communication.pdf
- 358 9. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The Role of
359 Antibody Testing for SARS-CoV-2: Is There One? *J Clin Microbiol*. 2020; JCM.00797-
360 20. doi:10.1128/JCM.00797-20
- 361 10. Venter M, Richter K. Towards effective diagnostic assays for COVID-19: a review. *J*
362 *Clin Pathol*. 2020; jclinpath-2020-206685. doi:10.1136/jclinpath-2020-206685
- 363 11. Haute Autorité de Santé. La HAS se prononce sur les tests sérologiques rapides –
364 TDR, TROD, autotests – dans la lutte contre le COVID-19. Available: [https://www.has-
365 sante.fr/jcms/p_3185170/fr/la-has-se-prononce-sur-les-tests-serologiques-rapides-tdr-
366 trod-autotests-dans-la-lutte-contre-le-covid-19](https://www.has-sante.fr/jcms/p_3185170/fr/la-has-se-prononce-sur-les-tests-serologiques-rapides-tdr-trod-autotests-dans-la-lutte-contre-le-covid-19)
- 367 12. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. *Immunity*.
368 2020/05/19 ed. 2020;52: 737–741. doi:10.1016/j.immuni.2020.04.012


369

370

371 **Figures**

372

373 **Fig 1. Interpretation of results for COVID-RESTO®**



374

375